Published: November 2004
Website: November 2004
Joseph Proietto, Sir Edward Dunlop Medical Research Foundation Professor of Medicine, University of Melbourne and Department of Medicine, Heidelberg Repatriation Hospital, Austin Health, Melbourne, Australia
Reprinted from Australian Prescriber
2004;27(5):118-119 with permission.
Article reprinted in Prescriber Update 2004;25(2):20-22.
There is an increased risk of diabetes in patients with schizophrenia and this risk is elevated by some antipsychotic medications. The risk is greater with the atypical drugs clozapine and olanzapine and the low potency conventional antipsychotics than with risperidone or high potency conventional drugs. While weight gain may be a mechanism for the development of diabetes, a direct effect of these drugs on insulin action in muscle may also be an important contributor. Patients with major psychosis should be managed in the same way as other patients with diabetes, but difficulties in complying with diet, exercise and taking medication should be kept in mind. Treating cardiovascular risk factors is important.
Antipsychotic drugs and diabetes
Table 1: Classification of antipsychotic medications available in Australia
Mechanism of antipsychotic-induced diabetes
Table 2: Risk of developing diabetes with antipsychotic medication
Management of diabetes in patients with schizophrenia
An impaired action of insulin (insulin resistance) in patients with schizophrenia was reported over 55 years ago and later confirmed in Australia.1 The prevalence of diabetes in patients with schizophrenia was found to be higher than in the general population even before the widespread use of antipsychotic medication. The mechanisms underlying the relationship between schizophrenia and diabetes remain unknown.
It is now clear that some antipsychotic medications increase the risk of diabetes in patients with schizophrenia. Rarely, this may present as diabetic ketoacidosis. The atypical medications (Table 1) have become widely used because of their lower rate of extrapyramidal adverse effects compared to older classes of medication such as the phenothiazines and the butyrophenones. However, while some of the atypical drugs are better tolerated, they also increase the incidence of diabetes. In patients younger than 40 years of age, the odds ratio for developing diabetes is 1.63 if they are taking an atypical antipsychotic.2
|Atypical||Low potency* conventional||High potency conventional|
* Low potency is defined as 'equivalent or less potent than chlorpromazine'.10
a With the exception of aripiprazole, all the other antipsychotics are available in New Zealand
Not all antipsychotics increase the risk of diabetes to the same extent.3 In a survey of two large US health plans, the risk of developing diabetes over a year was found to be higher with olanzapine and 'low potency' conventional antipsychotics, but not with risperidone or 'high potency' conventional drugs (Table 2).4 In one prospective study 36.6% of patients treated with clozapine developed diabetes over a five-year period.5
The mechanisms responsible for the elevated risk of diabetes associated with some antipsychotics are not fully understood. It is known that the atypical antipsychotics and some of the low potency conventional antipsychotics cause weight gain6 and that, at least for olanzapine and clozapine, the magnitude of this weight gain correlates with the magnitude of the therapeutic response.7 The weight gain in response to antipsychotic medication is also variable. Clozapine and olanzapine cause the greatest gain, risperidone and quetiapine moderate gain, and aripiprazole and amisulpride the least gain.8 However, at present insufficient information is available about some of the newer drugs to know what their weight gain and diabetogenic potential will prove to be with more widespread use.
Obesity can precipitate diabetes in susceptible people so weight gain is one mechanism for the increased incidence in diabetes. However, the fact that hyperglycaemia improves quickly after stopping the antipsychotic medication and that diabetes can appear in some patients who do not put on weight, suggests that other mechanisms must be involved. A prospective study of 82 patients treated with clozapine also found that the risk of developing diabetes was independent of weight gain.5
|Drug||Number of patients||12-month odds ratio (95% CI)|
|Low potency conventional||302||4.972 (CI 1.967-12.612)†|
|High potency conventional||785||1.945 (CI 0.794-4.786)|
|Olanzapine||656||4.289 (CI 2.102-8.827)†|
|Risperidone||849||1.024 (CI 0.351-3.015)|
CI confidence interval; † significant (p < 0.05) compared to untreated patients
Diabetes related to antipsychotic medication is associated with high insulin concentrations, so it seems that these drugs may aggravate the insulin resistance that already exists in patients with schizophrenia. While some of this is no doubt related to weight gain, it has also been shown that antipsychotics inhibit glucose transport into muscle. There is a strong correlation between the ability of these drugs to inhibit glucose transport in vitro and their capacity to induce hyperglycaemia in vivo.9
What needs to be taken into account when treating someone coping with the dual problems of schizophrenia and diabetes?
b Neither glimepiride nor modified-release gliclazide are marketed in New Zealand
The management of diabetes in patients with a major psychiatric illness is problematic. Weight loss or prevention of weight gain should always be attempted because of the known benefits to other comorbidities associated with obesity. However, even if successful, this approach alone may not reduce the risk of developing or worsening diabetes.
Conflict of interest: none declared.